Physician profile
Thomas Gleason
NPI 1841244597
$6,121.30
in general payments reported to CMS, 2019-2025
8 companies · $2,171 in 2025
The $2,171 reported for 2025 was more than what a typical Orthopaedic Surgery provider received nationally (typical 2025 total: $569).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $19.31 · 2020: $2,282 · 2021: $580 · 2022: $250 · 2023: $505 · 2024: $314 · 2025: $2,171.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $1,668 · Food and Beverage: $1,322.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $1,668.00 |
| Food and Beverage | $1,321.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Baxter Healthcare | $3,428.00 | 2020-2025 | |
| Medtronic, INC. | $1,095.79 | 2021-2025 | Cd Horizon Spinal System, Anteralign Spinal System With Titan Nanolock Surface Technology, Osteocool Rf Ablation System |
| Relievant Medsystems, INC. | $495.92 | 2020 | |
| Si-Bone, INC. | $302.80 | 2020-2023 | |
| Orthofix Medical, INC. | $253.04 | 2023-2025 | Shoreline Asc, Cervical-Stim, Physio-Stim |
| Arteriocyte Medical Systems, INC. | $238.01 | 2025 | Magellan |
| Abbott Laboratories | $176.66 | 2019-2024 | Eterna |
| Stryker Corporation | $131.08 | 2021-2023 | Spinejack |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Gleason listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.